BioSpace News Archive

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences in December: Piper Sandler 32nd Annual Virtual Healthcare Conference Evercore ISI 3 rd Annual HealthCONx Virtual Conference on Thursday, December 3, 2020 at 12:10pm ET A webcast

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in December. Piper Sandler 32 nd Annual Virtual Healthcare Conference Format: Fireside chat with c

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that on November 23, 2020 , the NYSE American LLC (“NYSE American”), the Company’s curre

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced that it has signed an agreement to become a provider in the America’s Choice Provider Network.

Signifier Medical Technologies (“Signifier/the Company”), an innovator in the sleep disordered breathing market, is pleased to announce the appointment of Alastair Maxwell as Chief Financial Officer with immediate effec

RRD International, a specialized product development company that provides strategic and operational support to biopharmaceutical companies and investors, announced it has been acquired by Uniphar plc, a Dublin, Ireland based company.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the 2020 Piper Sandler Healthcare Conference, which is scheduled to take place from December 1 – 3, 2020. The conference will be held in a virt

Cohealo, the first sharing economy company in healthcare, announced a group purchasing agreement with Premier.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma First immunotherapy to be approved for a gastroesophageal cancer in the European Union Approval based on Phase 3 ATTRACTION-3 trial showing statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy

– First RNAi Therapeutic Approved in U.S. for Use in Both Children and Adults, and Third RNAi Medicine to Receive FDA Approval in Less than Three Years – – Approval Based on Results from Both ILLUMINATE-A and ILLUMINATE-B Phase 3 Studies, Demonstrating Clinically Significant Reductions in Urinary Oxalate and Encouraging Safety and Tolerability Across a Broad Spectrum of Patient Ages –